This page keeps track of new/upcoming treatment options for X-linked hypophosphatemia (XLH). What’s in development? What’s promising? What’s available soon? Find out below… Current topics include MAPK inhibitors, KRN23 (burosumab), cinacalcet, phosphate metabolism, gene therapy, and more.
Last updated: 4 years ago
Subscribe
News
Research
- Alterations of bone material properties in adult patients with X-linked hypophosphatemia (XLH) Jun 30, 2020
- Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial May 8, 2020
- New Developments in the Treatment of X-Linked Hypophosphataemia: Implications for Clinical Management Jan 22, 2020
